We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Expands Lilly’s Altima Use to Single Agent Maintenance Therapy
FDA Expands Lilly’s Altima Use to Single Agent Maintenance Therapy
October 26, 2012
The FDA has approved Eli Lilly’s Alimta for use as a single agent for continuous maintenance treatment of nonsquamous non-small cell lung cancer (NS NSCLC) based on new clinical data.